1. Home
  2. Pharma & Healthcare
  3. Global Antisense and RNAi Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025

Global Antisense and RNAi Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025

Publication Month: Feb 2020 | No. of Pages: 103 Published By: Global Info Research
Single User License: US $ 3480
Corporate User License: US $ 6960

Market Overview
The global Antisense and RNAi Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Antisense and RNAi Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Antisense and RNAi Therapeutics market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Antisense and RNAi Therapeutics market has been segmented into:
RNA Interference
Antisense RNA

By Application, Antisense and RNAi Therapeutics has been segmented into:
Hospital
Clinic

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Antisense and RNAi Therapeutics market presented in the report. This section sheds light on the sales growth of different regional and country-level Antisense and RNAi Therapeutics markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Antisense and RNAi Therapeutics market.

The report offers in-depth assessment of the growth and other aspects of the Antisense and RNAi Therapeutics market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Antisense and RNAi Therapeutics Market Share Analysis
Antisense and RNAi Therapeutics competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Antisense and RNAi Therapeutics sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Antisense and RNAi Therapeutics sales, revenue and market share for each player covered in this report.

The major players covered in Antisense and RNAi Therapeutics are:
Tekmira Pharmaceuticals
Santaris
Antisense Therapeutics
Arbutus Biopharma
Sirnaomics
Alnylam Pharmaceuticals
Isis Pharmaceuticals
Silence Therapeutics
Roche

Table of Contents

1 Antisense and RNAi Therapeutics Market Overview
1.1 Product Overview and Scope of Antisense and RNAi Therapeutics
1.2 Classification of Antisense and RNAi Therapeutics by Type
1.2.1 Global Antisense and RNAi Therapeutics Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Antisense and RNAi Therapeutics Revenue Market Share by Type in 2019
1.2.3 RNA Interference
1.2.4 Antisense RNA
1.3 Global Antisense and RNAi Therapeutics Market by Application
1.3.1 Overview: Global Antisense and RNAi Therapeutics Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Antisense and RNAi Therapeutics Market by Regions
1.4.1 Global Antisense and RNAi Therapeutics Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Antisense and RNAi Therapeutics (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Antisense and RNAi Therapeutics Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Antisense and RNAi Therapeutics Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Antisense and RNAi Therapeutics Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Antisense and RNAi Therapeutics Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Antisense and RNAi Therapeutics Status and Prospect (2015-2025)
2 Company Profiles
2.1 Tekmira Pharmaceuticals
2.1.1 Tekmira Pharmaceuticals Details
2.1.2 Tekmira Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Tekmira Pharmaceuticals SWOT Analysis
2.1.4 Tekmira Pharmaceuticals Product and Services
2.1.5 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.2 Santaris
2.2.1 Santaris Details
2.2.2 Santaris Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Santaris SWOT Analysis
2.2.4 Santaris Product and Services
2.2.5 Santaris Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.3 Antisense Therapeutics
2.3.1 Antisense Therapeutics Details
2.3.2 Antisense Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Antisense Therapeutics SWOT Analysis
2.3.4 Antisense Therapeutics Product and Services
2.3.5 Antisense Therapeutics Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.4 Arbutus Biopharma
2.4.1 Arbutus Biopharma Details
2.4.2 Arbutus Biopharma Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Arbutus Biopharma SWOT Analysis
2.4.4 Arbutus Biopharma Product and Services
2.4.5 Arbutus Biopharma Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.5 Sirnaomics
2.5.1 Sirnaomics Details
2.5.2 Sirnaomics Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Sirnaomics SWOT Analysis
2.5.4 Sirnaomics Product and Services
2.5.5 Sirnaomics Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.6 Alnylam Pharmaceuticals
2.6.1 Alnylam Pharmaceuticals Details
2.6.2 Alnylam Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Alnylam Pharmaceuticals SWOT Analysis
2.6.4 Alnylam Pharmaceuticals Product and Services
2.6.5 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.7 Isis Pharmaceuticals
2.7.1 Isis Pharmaceuticals Details
2.7.2 Isis Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Isis Pharmaceuticals SWOT Analysis
2.7.4 Isis Pharmaceuticals Product and Services
2.7.5 Isis Pharmaceuticals Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.8 Silence Therapeutics
2.8.1 Silence Therapeutics Details
2.8.2 Silence Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Silence Therapeutics SWOT Analysis
2.8.4 Silence Therapeutics Product and Services
2.8.5 Silence Therapeutics Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.9 Roche
2.9.1 Roche Details
2.9.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Roche SWOT Analysis
2.9.4 Roche Product and Services
2.9.5 Roche Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Antisense and RNAi Therapeutics Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Antisense and RNAi Therapeutics Players Market Share
3.2.2 Top 10 Antisense and RNAi Therapeutics Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Antisense and RNAi Therapeutics Revenue and Market Share by Regions
4.2 North America Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
4.3 Europe Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
4.5 South America Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
5 North America Antisense and RNAi Therapeutics Revenue by Countries
5.1 North America Antisense and RNAi Therapeutics Revenue by Countries (2015-2020)
5.2 USA Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
5.3 Canada Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
5.4 Mexico Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
6 Europe Antisense and RNAi Therapeutics Revenue by Countries
6.1 Europe Antisense and RNAi Therapeutics Revenue by Countries (2015-2020)
6.2 Germany Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
6.3 UK Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
6.4 France Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
6.5 Russia Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
6.6 Italy Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Antisense and RNAi Therapeutics Revenue by Countries
7.1 Asia-Pacific Antisense and RNAi Therapeutics Revenue by Countries (2015-2020)
7.2 China Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
7.3 Japan Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
7.4 Korea Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
7.5 India Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
8 South America Antisense and RNAi Therapeutics Revenue by Countries
8.1 South America Antisense and RNAi Therapeutics Revenue by Countries (2015-2020)
8.2 Brazil Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
8.3 Argentina Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Antisense and RNAi Therapeutics by Countries
9.1 Middle East & Africa Antisense and RNAi Therapeutics Revenue by Countries (2015-2020)
9.2 Saudi Arabia Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
9.3 UAE Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
9.4 Egypt Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
9.5 South Africa Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Antisense and RNAi Therapeutics Revenue and Market Share by Type (2015-2020)
10.2 Global Antisense and RNAi Therapeutics Market Forecast by Type (2019-2024)
10.3 RNA Interference Revenue Growth Rate (2015-2025)
10.4 Antisense RNA Revenue Growth Rate (2015-2025)
11 Global Antisense and RNAi Therapeutics Market Segment by Application
11.1 Global Antisense and RNAi Therapeutics Revenue Market Share by Application (2015-2020)
11.2 Antisense and RNAi Therapeutics Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2015-2020)
11.4 Clinic Revenue Growth (2015-2020)
12 Global Antisense and RNAi Therapeutics Market Size Forecast (2021-2025)
12.1 Global Antisense and RNAi Therapeutics Market Size Forecast (2021-2025)
12.2 Global Antisense and RNAi Therapeutics Market Forecast by Regions (2021-2025)
12.3 North America Antisense and RNAi Therapeutics Revenue Market Forecast (2021-2025)
12.4 Europe Antisense and RNAi Therapeutics Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Antisense and RNAi Therapeutics Revenue Market Forecast (2021-2025)
12.6 South America Antisense and RNAi Therapeutics Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Antisense and RNAi Therapeutics Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

Tables and Figures

List of Tables

Table 1. Global Antisense and RNAi Therapeutics Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Antisense and RNAi Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Antisense and RNAi Therapeutics Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Antisense and RNAi Therapeutics Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Tekmira Pharmaceuticals Corporate Information, Location and Competitors
Table 6. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Major Business
Table 7. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Total Revenue (USD Million) (2017-2018)
Table 8. Tekmira Pharmaceuticals SWOT Analysis
Table 9. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product and Solutions
Table 10. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Santaris Corporate Information, Location and Competitors
Table 12. Santaris Antisense and RNAi Therapeutics Major Business
Table 13. Santaris Antisense and RNAi Therapeutics Total Revenue (USD Million) (2018-2019)
Table 14. Santaris SWOT Analysis
Table 15. Santaris Antisense and RNAi Therapeutics Product and Solutions
Table 16. Santaris Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Antisense Therapeutics Corporate Information, Location and Competitors
Table 18. Antisense Therapeutics Antisense and RNAi Therapeutics Major Business
Table 19. Antisense Therapeutics Antisense and RNAi Therapeutics Total Revenue (USD Million) (2017-2018)
Table 20. Antisense Therapeutics SWOT Analysis
Table 21. Antisense Therapeutics Antisense and RNAi Therapeutics Product and Solutions
Table 22. Antisense Therapeutics Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Arbutus Biopharma Corporate Information, Location and Competitors
Table 24. Arbutus Biopharma Antisense and RNAi Therapeutics Major Business
Table 25. Arbutus Biopharma Antisense and RNAi Therapeutics Total Revenue (USD Million) (2017-2018)
Table 26. Arbutus Biopharma SWOT Analysis
Table 27. Arbutus Biopharma Antisense and RNAi Therapeutics Product and Solutions
Table 28. Arbutus Biopharma Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Sirnaomics Corporate Information, Location and Competitors
Table 30. Sirnaomics Antisense and RNAi Therapeutics Major Business
Table 31. Sirnaomics Antisense and RNAi Therapeutics Total Revenue (USD Million) (2017-2018)
Table 32. Sirnaomics SWOT Analysis
Table 33. Sirnaomics Antisense and RNAi Therapeutics Product and Solutions
Table 34. Sirnaomics Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Alnylam Pharmaceuticals Corporate Information, Location and Competitors
Table 36. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Major Business
Table 37. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Total Revenue (USD Million) (2017-2018)
Table 38. Alnylam Pharmaceuticals SWOT Analysis
Table 39. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product and Solutions
Table 40. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Isis Pharmaceuticals Corporate Information, Location and Competitors
Table 42. Isis Pharmaceuticals Antisense and RNAi Therapeutics Major Business
Table 43. Isis Pharmaceuticals Antisense and RNAi Therapeutics Total Revenue (USD Million) (2017-2018)
Table 44. Isis Pharmaceuticals SWOT Analysis
Table 45. Isis Pharmaceuticals Antisense and RNAi Therapeutics Product and Solutions
Table 46. Isis Pharmaceuticals Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Silence Therapeutics Corporate Information, Location and Competitors
Table 48. Silence Therapeutics Antisense and RNAi Therapeutics Major Business
Table 49. Silence Therapeutics Antisense and RNAi Therapeutics Total Revenue (USD Million) (2017-2018)
Table 50. Silence Therapeutics SWOT Analysis
Table 51. Silence Therapeutics Antisense and RNAi Therapeutics Product and Solutions
Table 52. Silence Therapeutics Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Roche Corporate Information, Location and Competitors
Table 54. Roche Antisense and RNAi Therapeutics Major Business
Table 55. Roche Antisense and RNAi Therapeutics Total Revenue (USD Million) (2017-2018)
Table 56. Roche SWOT Analysis
Table 57. Roche Antisense and RNAi Therapeutics Product and Solutions
Table 58. Roche Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Global Antisense and RNAi Therapeutics Revenue (Million USD) by Players (2015-2020)
Table 60. Global Antisense and RNAi Therapeutics Revenue Share by Players (2015-2020)
Table 61. Global Antisense and RNAi Therapeutics Revenue (Million USD) by Regions (2015-2020)
Table 62. Global Antisense and RNAi Therapeutics Revenue Market Share by Regions (2015-2020)
Table 63. North America Antisense and RNAi Therapeutics Revenue by Countries (2015-2020)
Table 64. North America Antisense and RNAi Therapeutics Revenue Market Share by Countries (2015-2020)
Table 65. Europe Antisense and RNAi Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 66. Asia-Pacific Antisense and RNAi Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 67. South America Antisense and RNAi Therapeutics Revenue by Countries (2015-2020)
Table 68. South America Antisense and RNAi Therapeutics Revenue Market Share by Countries (2015-2020)
Table 69. Middle East and Africa Antisense and RNAi Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 70. Middle East and Africa Antisense and RNAi Therapeutics Revenue Market Share by Countries (2015-2020)
Table 71. Global Antisense and RNAi Therapeutics Revenue (Million USD) by Type (2015-2020)
Table 72. Global Antisense and RNAi Therapeutics Revenue Share by Type (2015-2020)
Table 73. Global Antisense and RNAi Therapeutics Revenue Forecast by Type (2021-2025)
Table 74. Global Antisense and RNAi Therapeutics Revenue by Application (2015-2020)
Table 75. Global Antisense and RNAi Therapeutics Revenue Share by Application (2015-2020)
Table 76. Global Antisense and RNAi Therapeutics Revenue Forecast by Application (2021-2025)
Table 77. Global Antisense and RNAi Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Antisense and RNAi Therapeutics Picture
Figure 2. Global Antisense and RNAi Therapeutics Revenue Market Share by Type in 2019
Figure 3. RNA Interference Picture
Figure 4. Antisense RNA Picture
Figure 5. Antisense and RNAi Therapeutics Revenue Market Share by Application in 2019
Figure 6. Hospital Picture
Figure 7. Clinic Picture
Figure 8. Global Antisense and RNAi Therapeutics Revenue (USD Million) and Growth Rate (2015-2025)
Figure 9. North America Antisense and RNAi Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 10. Europe Antisense and RNAi Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 11. Asia-Pacific Antisense and RNAi Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. South America Antisense and RNAi Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Middle East and Africa Antisense and RNAi Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Global Antisense and RNAi Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Global Antisense and RNAi Therapeutics Revenue Share by Players in 2019
Figure 16. Global Top 5 Players Antisense and RNAi Therapeutics Revenue Market Share in 2019
Figure 17. Global Top 10 Players Antisense and RNAi Therapeutics Revenue Market Share in 2019
Figure 18. Key Players Market Share Trend
Figure 19. Global Antisense and RNAi Therapeutics Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 20. Global Antisense and RNAi Therapeutics Revenue Market Share by Regions (2015-2020)
Figure 21. Global Antisense and RNAi Therapeutics Revenue Market Share by Regions in 2018
Figure 22. North America Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
Figure 23. Europe Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
Figure 24. Asia-Pacific Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
Figure 25. South America Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
Figure 26. Middle East and Africa Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
Figure 27. North America Antisense and RNAi Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 28. North America Antisense and RNAi Therapeutics Revenue Market Share by Countries in 2019
Figure 29. USA Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
Figure 30. Canada Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
Figure 31. Mexico Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
Figure 32. Europe Antisense and RNAi Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 33. Europe Antisense and RNAi Therapeutics Revenue Market Share by Countries in 2019
Figure 34. Germany Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
Figure 35. UK Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
Figure 36. France Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
Figure 37. Russia Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
Figure 38. Italy Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
Figure 39. Asia-Pacific Antisense and RNAi Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 40. Asia-Pacific Antisense and RNAi Therapeutics Revenue Market Share by Countries in 2019
Figure 41. China Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
Figure 42. Japan Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
Figure 43. Korea Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
Figure 44. India Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
Figure 45. Southeast Asia Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
Figure 46. South America Antisense and RNAi Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 47. South America Antisense and RNAi Therapeutics Revenue Market Share by Countries in 2019
Figure 48. Brazil Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
Figure 49. Argentina Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
Figure 50. Middle East and Africa Antisense and RNAi Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 51. Middle East and Africa Antisense and RNAi Therapeutics Revenue Market Share by Countries in 2019
Figure 52. Saudi Arabia Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
Figure 53. UAE Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
Figure 54. Egypt Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
Figure 55. South Africa Antisense and RNAi Therapeutics Revenue and Growth Rate (2015-2020)
Figure 56. Global Antisense and RNAi Therapeutics Revenue Share by Type (2015-2020)
Figure 57. Global Antisense and RNAi Therapeutics Revenue Share by Type in 2019
Figure 58. Global Antisense and RNAi Therapeutics Market Share Forecast by Type (2021-2025)
Figure 59. Global RNA Interference Revenue Growth Rate (2015-2020)
Figure 60. Global Antisense RNA Revenue Growth Rate (2015-2020)
Figure 61. Global Antisense and RNAi Therapeutics Revenue Share by Application (2015-2020)
Figure 62. Global Antisense and RNAi Therapeutics Revenue Share by Application in 2019
Figure 63. Global Antisense and RNAi Therapeutics Market Share Forecast by Application (2021-2025)
Figure 64. Global Hospital Revenue Growth Rate (2015-2020)
Figure 65. Global Clinic Revenue Growth Rate (2015-2020)
Figure 66. Global Antisense and RNAi Therapeutics Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 67. Global Antisense and RNAi Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 68. Global Antisense and RNAi Therapeutics Revenue Market Share Forecast by Regions (2021-2025)
Figure 69. North America Antisense and RNAi Therapeutics Revenue Market Forecast (2021-2025)
Figure 70. Europe Antisense and RNAi Therapeutics Revenue Market Forecast (2021-2025)
Figure 71. Asia-Pacific Antisense and RNAi Therapeutics Revenue Market Forecast (2021-2025)
Figure 72. South America Antisense and RNAi Therapeutics Revenue Market Forecast (2021-2025)
Figure 73. Middle East and Africa Antisense and RNAi Therapeutics Revenue Market Forecast (2021-2025)
Figure 74. Sales Channel: Direct Channel vs Indirect Channel




Companies Mentioned
Tekmira Pharmaceuticals
Santaris
Antisense Therapeutics
Arbutus Biopharma
Sirnaomics
Alnylam Pharmaceuticals
Isis Pharmaceuticals
Silence Therapeutics
Roche

Reason to Buy

  • Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The segment that is expected to dominate the Pharma & Healthcare Market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets